SGLT2与心血管和生殖系统疾病的关联:基于14项大规模随机试验的元分析
Lei Li1,2,3, Yun-Hua Dong1,2,3, Yun Bai1,2,3
1Department of Reproductive Medicine, The First People's Hospital of Yunnan Province, Kunming, Yunnan Province, China.
Endocrine
|November 29, 2023
概括
-葡萄糖携带载体2抑制剂 (SGLT2is) 在降低心力衰竭和高血压等心血管疾病方面显示出显著的益处. 这一元分析证实了它们对生殖系统的安全性,没有发现任何重大风险.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学 是一个学科.
背景情况:
- -葡萄糖携带载体2抑制剂 (SGLT2is) 已被确立为改善糖尿病,心力衰竭 (HF) 和衰竭患者的心脏结局.
- SGLT2的心血管和生殖安全概况需要在广泛的疾病中进行进一步的研究.
研究的目的:
- 研究SGLT2抑制剂与各种心血管和生殖疾病的风险之间的关联.
- 综合大规模随机试验的证据,以评估SGLT2的安全性和有效性.
主要方法:
- 对14项大型随机试验进行了元分析,每项试验包括1000多名参与者.
- 评估结果包括与心血管和生殖疾病相关的严重不良事件.
- 为了确定关联,计算了聚合风险比率 (RR) 和95%置信区间 (CI).
主要成果:
- SGLT2与13种心血管疾病的显著降低风险有关,包括慢性心力衰竭 (RR 0.70),充血性心力衰竭 (RR 0.74),急性心力衰竭 (RR 0.72),冠状动脉疾病 (RR 0.75),缺血性心肌病 (RR 0.72),心房动 (RR 0.88),胸 (RR 0.72),高血压 (RR 0.70).
- 在SGLT2is和18种生殖系统疾病之间没有发现显著的关联,例如腺菌症,子宫内膜增生和子宫.
- 观察到潜在的子宫脱落风险增加,但具有广泛的置信区间.
结论:
- 这一元分析再次证实SGLT2抑制剂在治疗慢性充血性心力衰竭方面的好处.
- 有证据表明,SGLT2抑制剂在降低急性心力衰竭,心肌梗塞,心律失常和高血压风险方面具有潜在的益处.
- SGLT2 抑制剂在生殖系统方面显示出一般安全的特征.
相关概念视频
01:27Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
01:23Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
182
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
182
01:24Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329
01:17Oral Hypoglycemic Agents: Sulfonylureas
212
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
212